Health
Trial: No Need to Stop RAS Inhibitors in COVID-19 – MedPage Today
REPLACE COVID trial supports findings from BRACE CORONA
Hospitalized COVID-19 patients may safely continue taking their angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the small REPLACE COVID trial.
The study’s primary hierarchical endpoint — a global rank score in which patients were ranked by the severity of their COVID disease course according to various biomarkers and clinical events, with a lower rank score meaning more severe COVID-19 hospitalization — was about the same whether people were…
-
General5 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business5 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General8 hours agoAlbanese beats drum on economy as trade clouds gather
-
General7 hours agoToo skewed, too gentlemanly | The Spectator Australia